Novastan argatroban thrombin inhibitor regulatory update

The FDA extended to Feb. 18 from Feb. 16 the review period for TXB's NDA for Novastan to treat heparin-induced thrombocytopenia (HIT) syndrome. The delay was due to FDA closings in January resulting f...